The injectable aesthetics market has a new player following the FDA's late Tuesday approval of laViv (azficel-T) from Exton, Pa.-based Fibrocell Science Inc., but don't expect the autologous cell therapy to go head-to-head – or face-to-face – with the market-leading injectable Botox (onabotulinumtoxin A).